精选中国远大集团有限责任公司简介中英文版资料

中国远大集团有限责任公司简介

Company Profile of China Grand Enterprises, Inc.

中国远大集团有限责任公司（以下简称中国远大集团）成立于1993年，系股份制集团公司，总部位于北京亚运村远大中心。作为一家经营管理型投资公司，中国远大集团主营业务涵盖医药健康、置业投资、贸易产业及金融服务等产业领域。

China Grand Enterprises, Inc. (hereinafter referred to as CGE), established in 1993, is a joint-stock group company, headquartered in Grand Place, Beijing Asian Games Village. As an investment company engaged in operation and management, CGE’s core businesses cover pharmaceuticals and healthcare, property investment, commercial trade business, financial services and other industries.

1、医药健康产业

在医药健康产业领域，中国远大集团已形成以华东医药股份有限公司为龙头企业的发酵技术产业发展平台，以远大医药（中国）有限公司为龙头企业的化学合成药产业发展平台，以拥有近三百年历史的雷允上药业集团公司为龙头企业的现代中药产业发展平台，以远大蜀阳药业为龙头企业的血液制品、生物疫苗及生物制药产业发展平台；提供化学制剂、中药制剂、以血液制品及疫苗为基础的生物制剂等三大类近千品种的成药制剂品种；生产多种大宗原料药和甾体激素类、肾上腺素类等多种特色原料药、精细化工中间体和保健品等多个类别的医药相关产品；已形成各专业领域的营销体系，多项产品通过欧洲COS认证和美国FDA 认证。

中国远大集团一直将医药新产品研发作为战略重点，持续投入专项资金，通过构建自主研发平台，产学研相结合和国际合作等多种方式，不断成功开发出新

产品投放市场；已经形成了集产品研发、生产、销售于一体，中西药并举，国际和国内市场共同发展的医药健康产业模式。

1. Pharmaceuticals and Healthcare Industry

In the field of pharmaceuticals and healthcare industry, CGE has established several core industrial platforms within her controlled subsidiary companies. These include Huadong Pharmaceutical Co. Ltd. that plays a leading role in fermentation-based pharmaceutical production, Grand Pharma (China) Co. Ltd. a leader in synthetic chemistry-based pharmaceutical production, Lei Yunshang Pharmaceutical Group with a nearly 300-year history operating in the production of modern Traditional Chinese Medicine, and Grand Shuyang Pharmaceutical Co., Ltd. focusing on the production of blood products, vaccines and other biopharmaceutical products. CGE pharmaceutical and healthcare industry produces nearly a thousand pharmaceutical products which belong to three major categories including synthetic chemical drugs, traditional Chinese medicines and biopharmaceuticals consisting mainly of blood products and vaccines. Among the products of CGE pharmaceutical and healthcare industry are included various bulk active pharmaceutical ingredients (APIs), steroid hormones, adrenalines and a variety of other specialty APIs, fine chemicals and chemical intermediates, healthcare products and various other classes of pharmaceutical related products. CGE pharmaceutical and healthcare industry has established marketing systems in various specific fields, and many products have passed European COS certifications and US FDA inspections.

CGE views her pharmaceutical R&D as having strategic importance and continues to invest a large amount of funds in specific areas. Multiple approaches through the build-up of internal R&D capacity, establishing alliances with academic institutions and international collaborations have resulted in the successful development and launch of many new products in recent years. CGE has built a comprehensive business model in her pharmaceuticals and healthcare industry that integrates R&D, production and marketing and distribution into one with a combination of traditional Chinese and Western medicines, and domestic and global market focuses.